[1] Hagström H, Talb?ck M, Andreasson A, et al. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology, 2020, 158: 200-214.
[2] Younossi ZM, Henry L. Are Noninvasive Scoring Systems for Persons With Chronic Liver Disease Ready for Prime Time? Gastroenterology, 2020, 158: 40-42.
[3] Angulo P, Bugianesi E, Bjornsson E S, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2013, 145: 782-789. e4.
[4] Hagström H, Nasr P, Ekstedt M, et al. Accuracy of noninvasive scoring systems in assessing risk of death and liver-related endpoints in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2019, 17: 1148-1156. e4.
[5] Siddiqui MS, Yamada G, Vuppalanchi R, et al. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol, 2019, 17: 1877-1885. e5.
[6] Chan WK, Mustapha NRN, Mahadeva S. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. Hepatol Int, 2015, 9: 594-602.
[7] Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology, 2019, 69: 1075-1086.
[8] Karsdal MA, Henriksen K, Nielsen MJ, et al. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol, 2016, 311: G1009-G1017.
[9] Ampuero J, Pais R, Aller R, et al. Development and validation of hepamet fibrosis scoring system-a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease With Advanced Fibrosis. Clin Gastroenterol Hepatol, 2020, 18: 216-225. e5.
[10] Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. Liver Int, 2017, 37: 1887-1896. |
